2877 — China Shineway Pharmaceutical Income Statement
0.000.00%
- HK$6.83bn
- HK$713.82m
- CNY4.52bn
- 91
- 88
- 64
- 97
Annual income statement for China Shineway Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,706 | 2,656 | 3,224 | 3,951 | 4,517 |
Cost of Revenue | |||||
Gross Profit | 1,982 | 1,988 | 2,410 | 2,938 | 3,394 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,061 | 2,244 | 2,502 | 3,033 | 3,274 |
Operating Profit | 645 | 412 | 721 | 918 | 1,243 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 643 | 395 | 720 | 917 | 1,240 |
Provision for Income Taxes | |||||
Net Income After Taxes | 503 | 295 | 557 | 723 | 970 |
Net Income Before Extraordinary Items | |||||
Net Income | 503 | 295 | 557 | 723 | 970 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 503 | 295 | 557 | 723 | 970 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.689 | 0.621 | 0.754 | 0.957 | 1.29 |
Dividends per Share | |||||
Special Dividends per Share |